These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22275177)

  • 1. Re: intradetrusor botulinum neurotoxin A (BoNT-A) injections decrease bladder fibrosis secondary to partial urethral obstruction in the male rat model. Neurourol urodyn 2012;31:564-70.
    Pascali MP; De Gennaro M; Mosiello G
    Neurourol Urodyn; 2012 Apr; 31(4):571. PubMed ID: 22275177
    [No Abstract]   [Full Text] [Related]  

  • 2. Intradetrusor botulinum neurotoxin A (BoNT-A) injections decrease bladder fibrosis secondary to partial urethral obstruction in the male rat model.
    Tinay I; Tanidir Y; Cikler E; Cetinel S; Tarcan T
    Neurourol Urodyn; 2012 Apr; 31(4):564-70. PubMed ID: 22275224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relief by botulinum toxin of voiding dysfunction due to prostatitis.
    Maria G; Destito A; Lacquaniti S; Bentivoglio AR; Brisinda G; Albanese A
    Lancet; 1998 Aug; 352(9128):625. PubMed ID: 9746032
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of botulinum toxin type a in the bladder wall of children with neurogenic bladder dysfunction: a comparison of histological features before and after injections.
    Pascali MP; Mosiello G; Boldrini R; Salsano ML; Castelli E; De Gennaro M
    J Urol; 2011 Jun; 185(6 Suppl):2552-7. PubMed ID: 21527192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of overactive bladder with botulinum toxin: are there more challenges to deal with?
    Apostolidis A
    Eur Urol; 2012 Sep; 62(3):515-7. PubMed ID: 22673007
    [No Abstract]   [Full Text] [Related]  

  • 6. Targets for botulinum toxin in the lower urinary tract.
    Cruz F
    Neurourol Urodyn; 2014 Jan; 33(1):31-8. PubMed ID: 23775898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins.
    Apostolidis A
    Expert Opin Pharmacother; 2011 May; 12(7):1029-39. PubMed ID: 21288184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A.
    Dolly JO; Lawrence GW
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S14-20. PubMed ID: 25042137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of botulinum neurotoxin type A (BoNTA) in urology.
    Apostolidis A; Fowler CJ
    J Neural Transm (Vienna); 2008; 115(4):593-605. PubMed ID: 18322639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and potential urological applications of botulinum toxin A.
    Jiang YH; Liao CH; Kuo HC
    Nat Rev Urol; 2015 Sep; 12(9):519-33. PubMed ID: 26260879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Mouttalib S; Khan S; Castel-Lacanal E; Guillotreau J; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    BJU Int; 2010 Dec; 106(11):1677-80. PubMed ID: 20590550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum injection is useless on fibrotic neuropathic bladders.
    Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
    J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tips and Tricks in Intra-Detrusor Botulinum Toxin A (BoNTA) Injections.
    Corcos J; Biardeau X; Aharony S
    World J Urol; 2015 Jun; 33(6):899-901. PubMed ID: 26217823
    [No Abstract]   [Full Text] [Related]  

  • 14. Botox injections may ease men's urinary woes.
    Health News; 2003 Nov; 9(11):15. PubMed ID: 14619824
    [No Abstract]   [Full Text] [Related]  

  • 15. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity.
    Harper M; Popat RB; Dasgupta R; Fowler CJ; Dasgupta P
    BJU Int; 2003 Aug; 92(3):325-6. PubMed ID: 12887493
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration.
    Datta SN; Roosen A; Pullen A; Popat R; Rosenbaum TP; Elneil S; Dasgupta P; Fowler CJ; Apostolidis A
    J Urol; 2010 Dec; 184(6):2578-85. PubMed ID: 21030043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
    Gutiérrez-Martín P; Vírseda-Chamorro M; Salinas Casado J; Gómez-Rodríguez A; Esteban-Fuertes M
    Actas Urol Esp; 2015 May; 39(4):217-21. PubMed ID: 25582926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
    Cruz F; Nitti V
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance?
    Pistolesi D; Giannarini G; Stampacchia G; Selli C
    Eur Urol; 2011 Oct; 60(4):872-3. PubMed ID: 21802198
    [No Abstract]   [Full Text] [Related]  

  • 20. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.